Programming

Hypertension 2020 Scientific Sessions

September 10–13, 2020
Hilton New Orleans Riverside | New Orleans, Louisiana

Sponsored by: Council on Hypertension
Council on Kidney in Cardiovascular Disease

Registration Information
Registration opens April 15, 2020

 


See more Registration and Housing information
Abstract Submission
Abstract submission is open from February 19–May 13, 2020




See details on Submission Categories, Rules and Guidelines

2020 schedule

This is where you'll find schedules-at-a-glance, final programs, the online program planner, and much more --- closer to the conference.

About This Meeting

Hypertension 2020 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

The planned agenda includes 18 sessions during 3½ days, with more than 500 presentations focused on recent advances in hypertension research including oral and poster presentations selected from abstracts submitted by clinical and basic researchers as well as the Primary Care and Clinical Practice Clinical Science Tracks for Clinicians.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
     
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
     
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
     
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
     
  5. Describe new and emerging strategies for treating resistant hypertension.
     
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.